ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma.
Yongfang Ma(Anhui University of Science and Technology), Xiaolong Tang(Anhui University of Science and Technology)
PubMed
January 1, 2023
Cited by 4
Related Papers
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
|International Journal of Medical Sciences|2021|38
BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
|BioMed Research International|2021|25
Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
|Journal of Cancer Research and Clinical Oncology|2020|19
Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells
|Translational Cancer Research|2020|1